Mazdutide 9 mg Application Accepted by NMPA
Slice of Healthcare Team
11/25/2025
Key highlights
- Supplementary application for 9 mg mazdutide accepted
- Potential novel drug for moderate to severe obesity in China
- Phase 3 study GLORY-2 showed significant weight loss
- Favorable safety profile with no new warnings
- Novel treatment alternative to metabolic surgery
Source: PR Newswire
Notable Quotes
“ The potent weight loss efficacy demonstrated by mazdutide 9 mg in the GLORY-2 study positions it as a highly promising alternative to metabolic surgery. ”
Professor Linong Ji, Leading Principal Investigator at Peking University People's Hospital
“ Mazdutide 9 mg is currently the only GLP-1 receptor agonist that achieves over 20% weight loss in obese adults without T2D. ”
Dr. Lei Qian, Chief R&D Officer at Innovent
Why this matters
The acceptance of the mazdutide 9 mg application by China's NMPA is a critical step towards addressing the pressing issue of obesity in the country, potentially improving health outcomes for millions struggling with weight management. This innovative treatment option could offer a non-invasive solution amid a landscape where surgical interventions are often the primary recommendation. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
